

The 2012 Otto Aufranc Award

The Interpretation of Metal Ion Levels in Unilateral and Bilateral Hip Resurfacing

Catherine Van Der Straeten MD, George Grammatopoulos MD,
Harinderjit S. Gill BEng, DPhil, Alessandro Calistri MD,
Patricia Campbell PhD, Koen A. De Smet MD

© The Association of Bone and Joint Surgeons® 2012

Abstract

Background The interpretation of metal ion concentrations and their role in clinical management of patients with metal-on-metal implants is still controversial.

Questions/Purposes We questioned whether patients undergoing hip resurfacing with no clinical problems could be differentiated from those with clinical (pain, loss of function) and/or radiographic (component malpositioning, migration, bone loss), problems based on metal ion levels, and if there was a threshold metal level that predicted the need for clinical intervention. Furthermore, we asked if

patient and implant factors differed between these functional groups.

Methods We retrospectively identified 453 unilateral and 139 bilateral patients with ion measurements at minimum followup of 12 months (mean, 4.3 years; range, 1–12.9 years). Patients were designated as well functioning or poorly functioning based on strict criteria. The acceptable upper levels within the well-functioning group were determined from the 75th percentile plus $1.5 \times$ interquartile range. The sensitivity and specificity of these levels to predict clinical problems were calculated.

Results Well-functioning group ions were lower than the poorly functioning group ion levels. The acceptable upper levels were: chromium (Cr) 4.6 µg/L, cobalt (Co) 4.0 µg/L unilateral and Cr 7.4 µg/L, Co 5.0 µg/L bilateral. The specificity of these levels in predicting poor function was high (95%) and sensitivity was low (25%). There were more males in the well-functioning group and more females and smaller femoral components in the poorly functioning group.

Conclusions Metal levels higher than these proposed safe upper limits can predict problems with metal-on-metal resurfacings and are important parameters in the management of at-risk patients.

Each author certifies that he or she, or a member of their immediate family, has no commercial associations (eg, consultancies, stock ownership, equity interest, patent/licensing arrangements, etc) that might pose a conflict of interest in connection with the submitted article.

All ICMJE Conflict of Interest Forms for authors and *Clinical Orthopaedics and Related Research* editors and board members are on file with the publication and can be viewed on request. Each author certifies that his or her institution approved the human protocol for this investigation, that all investigations were conducted in conformity with ethical principles of research, and that informed consent for participation in the study was obtained. This work was performed at the ANCA Medical Centre, Ghent, Belgium.

C. Van Der Straeten (✉)
Independent Consultant Clinical Research, Bosstraat 19,
9830 St-Martens-Latem, Belgium
e-mail: cathvds@telenet.be

G. Grammatopoulos, H. S. Gill
Nuffield Department of Orthopaedics, Rheumatology
and Musculoskeletal Sciences, University of Oxford, Botnar
Research Centre, Nuffield Orthopaedic Centre, Oxford, UK

A. Calistri
ANCA-Clinic Roma, Clinica Valle Giulia, Rome, Italy

P. Campbell
Implant Retrieval Lab, J. Vernon Luck Orthopaedic Research
Center, Orthopaedic Hospital, Los Angeles, CA, USA

K. A. De Smet
ANCA Medical Centre, Ghent, Belgium

Level of Evidence Level II, diagnostic study. See Guidelines for Authors for a complete description of levels of evidence.

Introduction

Metal-on-metal hip resurfacing arthroplasty (HRA) is a surgical option in the treatment of end-stage hip disease. Systemic levels of chromium (Cr) and cobalt (Co) ions in whole blood, serum, or urine reportedly correlate with levels measured in joint fluid [4] and with the linear [4] and volumetric [15] wear of the femoral component. During the run-in phase of metal-on-metal HRA, the ion levels rise to peak levels approximately 9 to 12 months followed by a leveling off or a slow decrease of the systemic Cr and Co concentrations once the lower wear steady-state phase is reached [11]. In patients with continuous elevated wear associated with edge loading resulting from component malpositioning (eg, steep acetabular component) [3] or with hip resurfacing designs with a lower coverage angle [16], metal ion levels increase further and are correlated with clinical symptoms and radiographic evidence of adverse reactions such as osteolysis [3, 7, 10, 16, 19]. Thus, once the running-in phase is completed, ie, after approximately 12 months, systemic Cr and Co concentrations are considered surrogate markers of in vivo wear and their measurement is advocated by regulatory bodies such as the Medicines and Healthcare products Regulatory Agency in the United Kingdom [21] and the Food and Drug Administration in the United States [6] as a screening tool for the malfunctioning of metal-on-metal hip arthroplasties.

Metal ion measurements allow the early detection of increased wear before extensive tissue destruction has occurred with a better outcome of revisions [5, 8]. The Medicines and Healthcare products Regulatory Agency is recommending additional investigations when Cr and/or Co levels exceed 7 µg/L, which may include cross-sectional imaging [21]. However, this limit is arbitrary and not supported by scientific data. Moreover, it only applies to unilateral metal-on-metal hip arthroplasty. For bilateral metal-on-metal hip arthroplasty, metal ion levels are vaguely considered to be approximately twice as high [10]. Rigorous safe upper limits of systemic Cr and Co concentrations with clinical importance have yet to be established for metal-on-metal hip arthroplasty in general and for metal-on-metal HRA in particular. Furthermore, the interpretation of systemic metal ion levels and their use in the diagnostic and therapeutic management of patients with metal-on-metal HRA has not been outlined and may be challenging in asymptomatic patients with elevated ion levels or symptomatic patients with low ion levels.

We therefore questioned whether: (1) patients undergoing hip resurfacing with no clinical problems could be differentiated from those with clinical and/or radiographic problems (evidence of component malpositioning, migration, loosening or periprosthetic bone loss) based on metal ion levels; (2) if there was a threshold metal level that predicted the need for clinical intervention; and (3) if patient and implant factors differed between these groups.

Patients and Methods

We retrospectively identified all patients with unilateral (n = 453) and bilateral (n = 139) HRAs in whom metal ion measurements were available after 12 months postoperatively (after the running-in phase) and operated on from 1998 to 2010. During that period, a total of 3454 HRAs were implanted by a single surgeon. We included only those patients for whom we had complete clinical and radiographic data available at last followup at more than 12 months postoperatively and included metal-on-metal HRAs of any design. We excluded patients with metal-on-metal THAs so as to avoid the additional ions from modular taper junctions. We also excluded patients with other possible sources of metal ions such as medication or food supplements containing Cr or Co, occupational exposure, or the presence of other metal implants such as THA, TKAs, spinal hardware, or metal dental implants; we also excluded patients with renal insufficiency or even slightly elevated creatinine levels. The mean age at first surgery was 53 years (range, 29–70 years). The primary diagnosis was osteoarthritis in 91% of the patients, avascular necrosis in 6%, and congenital dysplasia, inflammatory arthritis, and trauma each in 1%. There were 260 men (57%) and 193 women (43%) in the unilateral group and 78 men (56%) and 61 women (44%) in the bilateral group. The minimum length of followup was 1 year (mean, 4.3 years; range, 1–12 years) for patients with unilateral HRA and 1 year (mean, 5 years; range, 1–13 years) after the last resurfacing procedure for patients with bilateral HRA. No patients were recalled specifically for this study; all data were obtained from medical records and radiographs.

Sixteen patients received their HRA as part of bilateral procedures performed simultaneously. In the unilateral group, there were eight different hip resurfacing designs (Table 1). The most commonly implanted prosthesis was the BHR (Smith & Nephew, Memphis, TN, USA) (n = 288 [64%]) followed by the Conserve Plus (Wright Medical Technology, Memphis, TN, USA) (n = 128 [28%]), the ASR (DePuy, Warsaw, IN, USA) (n = 20 [4%]), the Durom (Zimmer, Warsaw, IN, USA) (n = 9 [2%]), and four other designs (< 1%). In the bilateral group, there were seven different HRA implant combinations. The most commonly

implanted prosthesis was the BHR (67%) and the most commonly encountered combination was a bilateral BHR ($n = 85$ [61%]) followed by a BHR-Conserve Plus combination ($n = 23$ [17%]) and a bilateral Conserve Plus ($n = 22$ [15%]); all other combinations occurred in less than 3%. The median femoral head size was 50 mm both in the unilateral (mean, 49.5 mm; range, 38–62 mm) and the bilateral group (mean, 49.6 mm; range, 38–58 mm).

Table 1. Demographics of the study population

Demographic	Unilateral hip resurfacing (N = 453)	Bilateral hip resurfacing (N = 139)
Age (years) at (first) primary surgery	53 (range, 29–70)	
Sex		
Male	260	78
Female	193	61
Primary diagnosis		
Primary osteoarthritis	414	126
Avascular necrosis	26	9
Congenital hip dysplasia	6	3
Inflammatory arthritis	4	1
Trauma	3	
Mean followup (years)	4.3 (range, 1.0–12.0)	5.0 (range, 1.0–12.9)
Femoral head size (mm)		
Mean	49.5 (range, 38–62)	49.6 (range, 38–58)
Median	50	50
Hip resurfacing designs	ASR 20	Bilateral BHR 85
Adept (Finsbury Instruments, Surrey, UK)	BHR 288	BHR + Conserve-Plus 23
ASR (DePuy, Warsaw, IN, USA)	Conserve Plus 128	Bilateral Conserve-Plus 22
BHR (Smith & Nephew, Memphis, TN, USA)	Durom 9	ASR + BHR 4
Conserve Plus (Wright Medical Technology, Memphis, TN, USA)	Adept 3	ASR + Conserve-Plus 3
Cormet (Corin Ltd, Cirencester, UK)	Recap 2	Mitch + Conserve-Plus 1
Durom (Zimmer, Warsaw, IN, USA)	Mitch 2	Recap + Conserve-Plus 1
Mitch (Stryker, Mahwah, NJ, USA)	Cormet 1	
Recap (Biomet Inc, Warsaw, IN, USA)		

Clinical followup evaluation for asymptomatic patients was typically done at 6 weeks and 1, 2, 5, and 10 years, but patients with pain were evaluated at the time of presentation to the clinic and more regularly as needed to monitor symptoms. The evaluation included reviewing patients' pain, walking, and function; calculating a Harris hip score; performing a ROM examination of the hips; and obtaining standing AP and lateral radiographs of the pelvis and resurfaced hips.

Two of us (GG, AC) independently measured acetabular component inclination and anteversion using Einzel Bild Röntgen Analyse (EBRA) [18]. The theoretical contact patch to rim (CPR) distance was calculated using the method proposed by Langton et al. [17] based on hip contact forces [2] taking into account the acetabular component orientation, the femoral component radius, and the functional coverage arc as described by Griffin et al. [9] as an indication of the in vivo area of cover of the femoral head by the acetabular component. A CPR distance of less than 10 mm is associated with a high risk of edge loading and subsequent increased wear [17]. All radiographs were evaluated for radiolucent lines, osteolysis, component loosening, or migration by the two observers (GG, AC) independently. Except for reactive lines, any change, even minor, from the postoperative radiographs was considered pathological and was noted. The correlation coefficient for intra- and interobserver reliability was 0.9 ($p < 0.01$).

We began obtaining metal ion measurements in 1999 for clinical trials and subsequently on a routine basis at every followup visit since the end of 2005. All patients' clinical, radiographic, and metal ion data are entered prospectively in a database designed for the followup of hip arthroplasties (OrthowaveTM, Aria Software Ltd, Arras, France). We collected blood samples for metal ion measurements in compliance with a recommended rigorous collection protocol [19] using an intravenous catheter (Becton Dickinson Insite-WTM, Sandy, UT, USA). After the catheter was introduced, the metal needle was withdrawn and the first 5 mL of blood was discarded to avoid possible metal contamination from the needle. We collected a subsequent second 5 mL of blood using approved metal-free vacuum collection tubes for metal ion measurements (Terumo Venosafe VF-106SAHL; Terumo Europe NV, Leuven, Belgium). There is no consensus to date on which matrix (whole blood or serum) is superior [19, 24]. We routinely use serum measurements that are performed at the Laboratory of Toxicology, University Hospital, Ghent, Belgium, using an inductive-coupled plasma mass spectrometry technique (ELAN DRC II; Perkin Elmer Life and Analytical Sciences, Shelton, CT, USA). The laboratory quotes its quantification limit as 0.5 µg/L with a reproducibility of 95%. The analyses are IQC and EQC controlled according to the QMEQAS (Quebec Multielement External Quality Assessment Scheme).

To address the first question, the cohort was divided into a well-functioning group and a poorly functioning group. The criteria to be fulfilled for allocation to the well-functioning group were rigorous: (1) no patient-reported hip complaints; (2) no surgeon-detected clinical findings; (3) Harris hip score higher than 95 points; (4) CPR distance greater than 10 mm; (5) no abnormal radiological findings; and (6) no further operation scheduled (Table 2). For a HRA to be considered well functioning and to be allocated to that group, all of the criteria had to be fulfilled, whereas bilateral patients had to fulfill all criteria for both hips. A patient with any deviation from these criteria, even for only one criterion in one hip, was allocated to the other group. The well-functioning group consisted of 251 patients with a unilateral HRA (55%) and 58 patients with bilateral HRA (42%), whereas 202 patients with a unilateral and 81 patients with a bilateral HRA were identified to have clinical and/or radiographic problems that placed them in the poorly functioning group.

The questions were examined as follows: (1) the differences in serum metal ion levels between the well-functioning and poorly functioning groups were examined

using the Mann-Whitney U and the Kruskal-Wallis tests to determine if ion levels could be used to differentiate between these groups; (2) to establish a threshold metal level that predicted the need for intervention, the guideline upper limit ion level values for well-functioning implants was established as the highest values, which were not considered as outliers. The definition used for the upper limit was (75th percentile) + $1.5 \times$ (interquartile range) = top margin of the box and whisker plot [12]. The sensitivity and specificity of these upper limits of both Cr and Co for diagnosing clinical problems were examined by performing receiver operating characteristic (ROC) analyses [26]; (3) finally, the patient and implant factors, including sex, component size, cup inclination, coverage arc, and CPR distance, of the well-functioning group were compared with corresponding values of poorly functioning patients using parametric or nonparametric tests as necessary. IBM SPSS Statistics Version 19 (SPSS, an IBM Company, Chicago, IL, USA) was used.

Results

When the ion levels were compared between the two groups, higher ion levels were found in the poorly functioning group ($p < 0.001$) (Table 3). The median ion levels in the unilateral well-functioning group were Cr: 1.6 $\mu\text{g/L}$, Co: 1.5 $\mu\text{g/L}$ versus Cr: 2.5 $\mu\text{g/L}$, Co: 2.1 $\mu\text{g/L}$ in the other group ($p < 0.001$; Fig. 1A). Similarly in the bilateral patients, median levels were higher in the poorly functioning group ($p < 0.001$) (Fig. 1B). Patients with unilateral HRAs had lower ion levels compared with bilateral HRAs ($p < 0.001$).

The upper ion limits differentiating the two groups were established as Cr: 4.6 $\mu\text{g/L}$ and Co: 4.0 $\mu\text{g/L}$ for unilateral and Cr: 7.4 $\mu\text{g/L}$ and Co: 5.0 $\mu\text{g/L}$ for bilateral HRA (Fig. 2). Ion levels higher than these were correlated with clinical symptoms ($p < 0.001$) and with risk factors for

Table 2. Criteria for allocation to the well-functioning hip resurfacing arthroplasty group*

Number	Criteria for allocation to the well-functioning hip resurfacing arthroplasty group*
1	No patient-reported hip complaints
2	No surgeon-detected clinical findings
3	Harris hip score > 95 points
4	CPR distance > 10 mm
5	No abnormal radiological findings
6	No further hip operation scheduled

* All criteria had to be fulfilled for a hip resurfacing arthroplasty (HRA) to be allocated to the well-functioning group. For bilateral HRA, all criteria had to be fulfilled for both hips; CPR = contact patch to rim distance.

Table 3. Serum chromium (Cr) and cobalt (Co) ion levels in the well-functioning and poorly functioning unilateral and bilateral HRA*

Descriptive statistics	Unilateral HRA (n = 453)				Bilateral HRA (n = 139)			
	Well-functioning serum levels ($\mu\text{g/L}$)		Poorly functioning serum levels ($\mu\text{g/L}$)		Well-functioning serum levels ($\mu\text{g/L}$)		Poorly functioning serum levels ($\mu\text{g/L}$)	
	Cr	Co	Cr	Co	Cr	Co	Cr	Co
Mean	2.0	1.8	7.3	6.6	3.8	2.8	10.7	8.5
Median	1.6	1.5	2.5	2.1	3.3	2.4	6.1	4.2
95% CI	1.8–2.2	1.6–1.9	5.1–9.0	4.5–8.6	3.2–4.5	2.4–3.3	6.8–14.2	4.7–11.9
Range	0.5–12.8	0.5–9.9	0.5–146	0.5–125	0.8–16.8	0.5–10.2	2.0–104.7	0.7–95.6
SD	1.5	1.2	17.3	18.1	2.7	1.9	16.0	18.5

* The difference in Cr and Co ion levels between well-functioning and poorly functioning groups is statistically significant at the $p < 0.001$ level for unilateral and bilateral HRA (Mann-Whitney U test); HRA = hip resurfacing arthroplasty; CI = confidence interval.




Fig. 1A–B (A) Box plots of serum Cr and Co levels in the well-functioning and poorly functioning groups for unilateral HRA. Well-functioning group patients have lower ($p < 0.001$) levels compared with poorly functioning group patients. There is a predominance of females among the outliers. (B) Box plots of serum Cr and Co levels

in the well-functioning and poorly functioning groups for bilateral HRA. Like in the unilateral group, well-functioning group patients have lower ($p < 0.001$) levels compared with poorly functioning group patients and there is a predominance of females among the outliers.

high wear, ie, smaller component size (Cr: $p < 0.001$, Co: $p = 0.002$), smaller cup coverage arc ($p < 0.001$), smaller CPR distance ($p < 0.001$), and higher cup inclination ($p < 0.001$). From the ROC analyses, both Cr and Co levels were better than chance ($p < 0.001$) at diagnosing clinical problems (Fig. 3A–B). For unilateral HRA, sensitivity and specificity of the well-functioning group upper limits in predicting poor function were, respectively, 25% and 95% for Cr and 22% and 96% for Co (Fig. 3A). Odds ratios of having a poorly functioning HRA were 6.0 for Cr > 4.6 µg/L and 5.9 for Co > 4.0 µg/L. For levels higher than 10 µg/L, the specificity of predicting clinical problems was 100%. For bilateral HRA, sensitivity and specificity of the well-functioning group upper levels were, respectively, 43% and 93% for Cr and 38.6% and 91% for Co (Fig. 3B). The odds of having a poorly functioning HRA were 8.7 for Cr > 7.4 µg/L and 6.0 for Co > 5.0 µg/L.

The well-functioning group contained more males (57% unilateral, 61% bilateral) compared with the poorly functioning group (Fig. 4A–B) and larger sized components. A ≥ 50 -mm femoral component had 64% chance of being in the well-functioning group compared with 38% for a < 50 -mm component. There was no sex difference in the < 50 -mm size group but for ≥ 50 -mm sizes, females still had a higher chance of being in the poorly functioning group (59% versus 33% of males; $p = 0.004$). Female




Fig. 2 Acceptable upper limits of Cr and Co levels for unilateral and bilateral HRA were established as the highest values, which were not considered as outliers for the well-functioning group patients. The definition used for the upper limit was (75th percentile) + $1.5 \times$ (interquartile range) = top margin of the box and whisker plot [12]. Lower ion levels ($p < 0.001$) were found with unilateral HRA compared with bilateral HRA.

patients predominated in the ion level outliers (Fig. 1A–B). Implant designs were differently distributed between the two groups for unilateral but not for bilateral patients; 66% of unilateral patients with a Conserve Plus were in the




Fig. 3A–B (A) ROC curve demonstrating the power (sensitivity and specificity) of serum Cr and Co for diagnosing clinically relevant problems in unilateral HRA. For Cr, area under the curve (AUC) was 0.67 (0.62–0.72), whereas for Co, AUC was 0.65 (0.59–0.70). Sensitivity and specificity of the upper limits in predicting poor function were, respectively, 25% and 95% for Cr and 22% and 96%

for Co. (B) ROC curve demonstrating the power (sensitivity and specificity) of serum Cr and Co for diagnosing clinically relevant problems in bilateral HRA. For Cr, AUC was 0.79 (0.71–0.86); for Co, AUC was 0.76 (0.68–0.84). Sensitivity and specificity of the safe upper levels for bilateral HRA were, respectively, 43% and 93% for Cr and 38.6% and 91% for Co.




Fig. 4A–B (A) Differences in sex and component size between the well-functioning and poorly functioning group in unilateral HRA. The majority of males (57%) were in the well-functioning group compared with the majority of females (64%) who were in the poorly functioning group. Well-functioning group patients had larger sized components (mean femoral head size, 50.4 mm) compared with poorly functioning group patients (mean, 48.6 mm) ($p < 0.001$).

(B) Differences in sex and component size between the well-functioning and poorly functioning groups in bilateral HRA. Like with unilateral HRA, the majority of males (61%) were in the well-functioning group compared with the majority of females (72%) in the poorly functioning group. Optimum group patients had larger sized components (mean femoral head size, 51.5 mm) compared with poorly functioning group patients (mean, 48.0 mm) ($p < 0.001$).

well-functioning group versus 43.5% for ASR, 41.5% for BHR, and 11% for Durom ($p = 0.014$). Patients receiving the Conserve Plus and Durom also had lower ($p < 0.001$) ions and greater CPR distance compared with patients receiving ASR and BHR. For bilateral HRA, different implant combinations had similar ion levels ($p = 0.25$) and a similar risk ratio of being in the poorly functioning group ($p = 0.45$).

Discussion

Metal ion levels have been used as a surrogate marker for wear of metal-on-metal hip arthroplasties [3, 4, 7, 10, 15, 16, 19, 21]. At our institution, metal ion measurements have been collected on a large number of patients undergoing HRA, initially only when a malfunctioning prosthesis was suspected [3]. Since 2006, metal ion measurements are part of our routine clinical followup also testing asymptomatic patients and those without apparent risk for high wear. All data are entered prospectively into a database. The purpose of this study was to use these data to find threshold levels of ions differentiating well-functioning and poorly functioning HRA and to determine which patient and implant factors were associated with those groups. The results confirm that ion measurements are an important diagnostic tool in the management of patients with HRA [4].


We acknowledge limitations to our study. First, it is not always straightforward to interpret ion levels in certain clinical situations such as symptomatic patients with low levels or asymptomatic patients with high levels. Metal ions are an adjunct to clinical and radiographic evaluations and should be considered as part of the whole clinical picture. For this reason, we have developed a clinical

management algorithm that incorporates our findings with our clinical experience and wear measurements from explants (Fig. 5). Second, the strict criteria that were used to assign patients to the well-functioning or poorly functioning groups may have resulted in lower than expected sensitivity of the threshold levels to predict poorly functioning implants, as discussed subsequently.

The findings of the present study confirm previous reports that both unilaterally and bilaterally resurfaced patients with well-functioning implants have low systemic metal ion levels [3, 4, 10, 16]. These levels are comparable to the 1- $\mu\text{g/L}$ level proposed as the indicator of well-functioning small-diameter metal-on-metal THAs [19]. By contrast, metal ion levels were higher in poorly functioning implants as previously reported [3, 4, 13, 15]. Per our strict criteria, implants suspected to be loose were assigned to the poorly functioning group and although loosening may be associated with higher ions [4, 5], this is not always the case. For example, we identified seven patients with loose Durom acetabular components with low ions (median, Cr: 0.8 $\mu\text{g/L}$, Co: 0.7 $\mu\text{g/L}$) and retrieval analysis of the explanted components demonstrated low wear (Fig. 6).

We propose that the upper metal ion levels in the well-functioning group can be considered as acceptable upper limits for unilateral (Cr: 4.6 $\mu\text{g/L}$, Co: 4.0 $\mu\text{g/L}$) and bilateral HRA (Cr: 7.4 $\mu\text{g/L}$, Co: 5.0 $\mu\text{g/L}$) patients and that these can serve as threshold levels for clinical management decisions. These levels are lower than the 7- $\mu\text{g/L}$ threshold recommended by the Medicines and Healthcare products Regulatory Agency [21], but this study had a very low tolerance for what was considered a poorly functioning hip. Seventeen patients undergoing unilateral HRA assigned to the poorly functioning group had levels $< 7 \mu\text{g/L}$ but higher than the proposed acceptable limits. The high specificity and odds ratios of the proposed limits in

Fig. 5 Diagnostic and therapeutic algorithm for the followup of a hip resurfacing arthroplasty is shown.



predicting problematic HRA are concurrent with reports [3, 4, 7, 10, 15, 16, 19] associating outlier values of metal ions with poorly functioning implants with high wear. However, because of low sensitivity, lower levels than the proposed limits may still be associated with poor function. The median ion levels of the poorly functioning group are only slightly higher than in the well-functioning group despite the statistically significant difference as a result of our strict criteria, which can include infection, metal allergy, or a loose, low-wear bearing with low ions.




Fig. 6A–B (A) Coordinate measuring machine (CMM)-derived wear depth map of a retrieved Durom HRA, head size 44 mm, showing low wear (maximum, 8.5 µm). This was implanted in a 26-year-old female patient with congenital hip dysplasia and revised after 19 months for cup loosening. Prerevision cup position measured with EBRA was 50° inclination and 14° anteversion. Metal ions prerevision were Cr: 1.6 µg/L, Co: 0.5 µg/L. (B) Same retrieved Durom HRA: scanning electron microscopy (SEM) picture of the bearing area approximately 5000× displaying only occasional scratches and a smooth background surface.

Certain patient and implant variables differed between well-functioning and poorly functioning implants. As previously reported [3, 4, 16, 20, 23], females and smaller head sizes (< 50 mm) are more at risk of having a problematic HRA associated with higher metal ion levels. These findings are consistent with Arthroplasty Registry reports [1, 22]. The effect of cup coverage angle on ion levels is illustrated by the comparison of different HRA designs. Implants with a larger functional articular arc (Durom, Conserve Plus) had lower ion levels compared with ASR and BHR designs with a smaller articular arc [15, 17], particularly in the smaller sizes. Cup malpositioning and impingement are associated with increased wear and higher metal ion levels [3, 10, 16]. Well-functioning bilateral HRAs have higher ion levels compared with well-functioning unilateral HRAs. Having bilateral HRAs increases the risk of having a problematic resurfacing with metal ion levels predominantly reflecting the wear condition of the worst implant.

To provide practical applications of our findings, we have developed an algorithm (Fig. 5). For ease of use, metal ion levels are subdivided into < 4 µg/L, 4 to 10 µg/L, 10 to 20 µg/L, or > 20 µg/L (Table 4). Symptomatic patients with low ion levels must be investigated thoroughly with blood tests and additional imaging for infection, soft tissue reactions possibly related to allergy, or component loosening. If a patient has elevated metal ion levels without clinical symptoms or radiographic changes,

Table 4. Practical classification of the metal ions levels (Cr and Co) for use with the diagnostic and therapeutic algorithm (Fig. 5)

Serum Cr/Co levels	After exclusion of other possible sources of metal ions
< 4 µg/L	Normal steady-state values; in the absence of clinical and radiographic symptoms, routine followup regime is further followed; safe upper limits unilateral HRA: Cr: 4.6 µg/L, Co: 4.0 µg/L
4–10 µg/L	Moderately elevated levels; additional investigations advocated; if no abnormalities are found and the patient is asymptomatic, a close clinical followup and remeasurement of metal ion levels is advisable; with bilateral HRA, safe upper limits are Cr: 7.4 µg/L, Co: 5.0 µg/L
10–20 µg/L	Sign of increased wear; repeated thorough diagnostic investigations
> 20 µg/L	Concerning as sign of high wear even in the absence of clinical or radiographic symptoms around the hip; thorough additional investigations necessary; Co levels > 20 µg/L may be associated with systemic toxicity; revision has to be considered

Cr = chromium; Co = cobalt; HRA = hip resurfacing arthroplasty.

cross-sectional imaging should be performed, which may reveal a soft tissue reaction [13], necessitating revision surgery. In case of minor, asymptomatic abnormalities such as a thickened hip capsule or a small fluid collection ($< 5 \text{ cm}^3$), with metal ion levels $< 20 \text{ }\mu\text{g/L}$, close clinical followup and sequential cross-sectional imaging are advocated. If all investigations fail to show any problem, the patient is followed yearly with a clinical, radiographic, and metal ions examination for 2 consecutive years. If no further increase or a decrease of ion levels is seen, the patient returns to the normal followup regime (1, 2, 3, 5, 10 years). In case of a continuous increase of metal ions, additional investigations are repeated.

Co ion levels above $20 \text{ }\mu\text{g/L}$ are a reason for serious concern because such levels have been associated with neurological, otological, and cardiac symptoms [25]. In those cases, a revision should be considered even with minor clinical symptoms. The use of metal ion measurements as a screening method for the early detection of increased wear before extensive soft tissue or bone destruction has occurred leads to a better outcome of HRA revisions [5, 14].

Acknowledgments We thank Dr Eddie Ebrahimzadeh for his advice regarding statistical analysis.

References

1. Australian Orthopaedic Association National Joint Replacement Registry. Annual report 2011. Published October 2011 and since then available at: www.dmac.adelaide.edu.au/aoanjrr/publications.jsp. Accessed October 15, 2011.
2. Bergmann G, Deuretzbacher G, Heller M, Graichen F, Rohlmann A, Strauss J, Duda GN. Hip contact forces and gait patterns from routine activities. *J Biomech*. 2001;34:859–871.
3. De Haan R, Pattyn C, Gill HS, Murray DW, Campbell PA, De Smet K. Correlation between inclination of the acetabular component and metal ion levels in metal-on-metal hip resurfacing replacement. *J Bone Joint Surg Br*. 2008;90:1291–1297.
4. De Smet K, De Haan R, Calistri A, Campbell PA, Ebrahimzadeh E, Pattyn C, Gill HS. Metal ion measurement as a diagnostic tool to identify problems with metal-on-metal hip resurfacing. *J Bone Joint Surg Am*. 2008;90(Suppl 4):202–208.
5. De Smet KA, Van Der Straeten C, Van Orsouw M, Doubi R, Backers K, Grammatopoulos G. Revisions of metal-on-metal hip resurfacing: lessons learned and improved outcome. *Orthop Clin N Am*. 2011;42:259–269.
6. Food and Drug Administration. FDA 522 guidance document. Available at: www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm072564.pdf. Accessed August 16, 2011.
7. Garbuz DS, Tanzer M, Greidanus NV, Masri BA, Duncan CP. The John Charnley Award: Metal-on-metal hip resurfacing versus large-diameter head metal-on-metal total hip arthroplasty: a randomized clinical trial. *Clin Orthop Relat Res*. 2010;468:318–325.
8. Grammatopoulos G, Grammatopoulos H, Pandit Y-M, Kwon R, Gundle P, McLardy-Smith D, Beard DW, Murray HS, Gill. Hip resurfacings revised for inflammatory pseudotumour have a poor outcome. *J Bone Joint Surg Br*. 2009;91:1019–1024.
9. Griffin WL, Nanson CJ, Springer BD, Fehring TK. Reduced articular surface of one-piece cups: a cause of runaway wear and early failure. *Clin Orthop Relat Res*. 2010;468:2328–2332.
10. Haddad FS, Thakrar RR, Hart AJ, Skinner JA, Nargol AV, Nolan JF, Gill HS, Murray DW, Blom AW, Case CP. Metal-on-metal bearings: the evidence so far. *J Bone Joint Surg Br*. 2011;93:572–579.
11. Heisel C, Streich N, Krachler M, Jakubowitz E, Kretzer JP. Characterization of the running-in period in total hip resurfacing arthroplasty: an in vivo and in vitro metal ion analysis. *J Bone Joint Surg Am*. 2008;90:125–133.
12. Hodge VJ, Austin J. A survey of outlier detection methodologies. *Artificial Intelligence Review*. 2004;22:85–126.
13. Kwon YM, Ostlere SJ, McLardy-Smith P, Athanasou NA, Gill HS, Murray DW. ‘Asymptomatic’ pseudotumors after metal-on-metal hip resurfacing arthroplasty: prevalence and metal ion study. *J Arthroplasty*. 2011;26:511–518.
14. Kwon YM, Xia Z, Glyn-Jones S, Beard D, Gill HS, Murray DW. Dose-dependent cytotoxicity of clinically relevant cobalt nanoparticles and ions on macrophages in vitro. *Biomed Mater*. 2009;4:025018.
15. Langton DJ, Joyce TJ, Jameson SS, Lord J, Van Orsouw M, Holland JP, Nargol AV, De Smet KA. Adverse reaction to metal debris following hip resurfacing: the influence of component type, orientation and volumetric wear. *J Bone Joint Surg Br*. 2011;93:164–171.
16. Langton DJ, Joyce TJ, Mangat N, Lord J, Van Orsouw M, De Smet K, Nargol AV. Reducing metal ion release following hip resurfacing arthroplasty. *Orthop Clin North Am*. 2011;42:169–180.
17. Langton DJ, Sprowson AP, Joyce TJ, Reed M, Carluke I, Partington P, Nargol AV. Blood metal ion concentrations after hip resurfacing arthroplasty: a comparative study of articular surface replacement and Birmingham Hip Resurfacing arthroplasties. *J Bone Joint Surg Br*. 2009;91:1287–1295.
18. Langton DJ, Sprowson AP, Mahadeva D, Bhatnagar S, Holland JP, Nargol AV. Cup anteversion post hip resurfacing arthroplasty: validation of EBRA and presentation of a simple clinical grading system. *J Arthroplasty*. 2010;25:607–613.
19. Mac Donald SJ, Brodner W, Jacobs JJ. A consensus paper on metal ions in metal-on-metal hip arthroplasties. *J Arthroplasty*. 2004;19(Suppl 3):12–16.
20. McBryde CW, Theivendran K, Thomas A, Treacy R, Pynsent PB. The influence of head size and sex on the outcome of Birmingham Hip Resurfacing. *J Bone Joint Surg Am*. 2010;92:105–112.
21. Medical device alert of the Medicines and Healthcare products Regulatory Agency on all metal-on-metal (MoM) hip replacements. MDA/2010/033. Issued April 22, 2010. Available at: www.mhra.gov.uk/Publications/Safetywarnings/MedicalDeviceAlerts/CON079157. Accessed April 22, 2010.
22. National Joint Registry for England and Wales. 8th annual report 2011. Available at: www.njrcentre.org.uk/njrcentre/AbouttheNJR/Publicationsandreports/Annualreports. Accessed September 15, 2011.
23. Nunley RM, Della Valle CJ, Barrack RL. Is patient selection important for hip resurfacing? *Clin Orthop Relat Res*. 2009;467:56–65.
24. Smolders JMH, Bisseling P, Hol A, Van Der Straeten C, Schreurs BW, van Susante JLC. Metal ion interpretation in resurfacing versus conventional hip arthroplasty and in whole blood versus serum. How should we interpret metal ion data? *Hip Int*. 2011;21:587–595.
25. Tower SS. Arthroprosthetic cobaltism: neurological and cardiac manifestations in two patients with metal-on-metal arthroplasty: a case report. *J Bone Joint Surg Am*. 2010;92:2847–2851.
26. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. *Clin Chem*. 1993;39:561–577.